Effectiveness of molnupiravir in high-risk patients: a propensity score matched analysis
R Najjar-Debbiny, N Gronich, G Weber… - Clinical infectious …, 2023 - academic.oup.com
Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis
R Najjar-Debbiny, N Gronich, G Weber… - Clinical Infectious …, 2023 - academic.oup.com
Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
[PDF][PDF] Effectiveness of Molnupiravir in High Risk Patients: a Propensity Score Matched Analysis
R Najjar-Debbiny, W Saliba - 2022 - researchgate.net
Abstract 1 Background: Molnupiravir was granted emergency use authorization for the
treatment of mild to 2 moderate COVID-19. In this study we used population-based real …
treatment of mild to 2 moderate COVID-19. In this study we used population-based real …
Effectiveness of molnupiravir in high-risk patients: a propensity score matched analysis.
R Najjar-Debbiny, N Gronich, G Weber, J Khoury… - 2022 - cabidigitallibrary.org
Background: Molnupiravir was granted emergency use authorization for the treatment of
mild to moderate coronavirus disease 2019 (COVID-19). In this study, we used population …
mild to moderate coronavirus disease 2019 (COVID-19). In this study, we used population …
Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis
R Najjar-Debbiny, N Gronich… - … publication of the …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
[PDF][PDF] Effectiveness of Molnupiravir in High Risk Patients: a Propensity Score Matched Analysis
R Najjar-Debbiny, W Saliba - 2022 - scholar.archive.org
Abstract 1 Background: Molnupiravir was granted emergency use authorization for the
treatment of mild to 2 moderate COVID-19. In this study we used population-based real …
treatment of mild to 2 moderate COVID-19. In this study we used population-based real …
Effectiveness of Molnupiravir in High Risk Patients: a Propensity Score Matched Analysis.
R Najjar-Debbiny, N Gronich, G Weber… - … Diseases: an Official …, 2022 - europepmc.org
Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate COVID-19. In this study we used population-based real-world data to evaluate …
to moderate COVID-19. In this study we used population-based real-world data to evaluate …
Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis.
R Najjar-Debbiny, N Gronich, G Weber… - Clinical Infectious …, 2023 - search.ebscohost.com
Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …